Andrew Hedin
Partner @ Bessemer Venture Partners
Boston, United States
Andrew Hedin is a Series B investor at Bessemer Venture Partners in Boston focused on Health Care and Biotechnology. Andrew Hedin is based out of Boston, Massachusetts, and is the Partner at Bessemer Venture Partners and Board of Director at Triana Biomedicines. Andrew Hedin attended The Wharton School.
- Total investments:
- 20
- Last investment:
- Lead investor:
- 55%
Last updated:
For AI agents: llms.txt
Industries Andrew Hedin invests in
Stages Andrew Hedin invests in
Countries Andrew Hedin invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 11 (55%)
- Biotechnology 7 (35%)
- Medical 6 (30%)
- Software 4 (20%)
- Artificial Intelligence 4 (20%)
Stage
- Series B 7 (35%)
- Seed 4 (20%)
- Series A 4 (20%)
- Series C 3 (15%)
- Series D 2 (10%)
Country
- United States 15 (75%)
- United Kingdom 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Soufflé Therapeutics is a biotechnology company specializing in the development of nucleic acid medicines designed for precise delivery and targeting of disease-causing cells. The company's mission is to create potent, precise, and safe medicines that can be tailored for a broad range of diseases by leveraging breakthroughs in genetic medicineand drug delivery technology. | $135M / Series B / Oct 13, 2026 | ||
| Converge Bio integrates Generative AI with biological data. Converge Bio mission is to empower biotech and pharmaceutical companies to discover and develop more effective drugs faster, utilizing the power of Large Language Models (LLMs) specifically trained on biological languages. | $25M / Series A / Jan 13, 2026 | ||
Triana Biomedicines
|
Triana Biomedicines is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. Triana’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art in silico tools, and bespoke chemical libraries. The research team has validated thebest-in-class platform and initiated multiple programs across different disease areas. | $120M / Series B / Dec 03, 2025 | |
| Plenful optimizes healthcare and pharmacy operations through intelligent workflow automation, data configuration and centralization, and machine learning. The company built a healthcare-focused AI automation platform to unburden staff, deliver meaningful financial and operational results, and drive more efficient patient care outcomes.Plenful islocated in San Francisco, California and is backed by leading healthcare and software investors.. | $50M / Series B / Apr 30, 2025 | ||
| Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development. Using its IMPACT™ platform, the company is addressing the central challenges of biologics discovery and development by fully integrating machine learning with the key elements ofbiologics drug discovery – structural biology, protein engineering, and translational immunology – to create optimized therapies on an accelerated path to patients. Seismic Therapeutic has an emerging pipeline of novel biologics to address adaptive immune system dysregulation to treat autoimmune diseases. | $121M / Series B / Dec 04, 2023 | ||
| Plenful optimizes healthcare and pharmacy operations through intelligent workflow automation, data configuration and centralization, and machine learning. The company built a healthcare-focused AI automation platform to unburden staff, deliver meaningful financial and operational results, and drive more efficient patient care outcomes.Plenful islocated in San Francisco, California and is backed by leading healthcare and software investors.. | $9M / Seed / Oct 03, 2023 | ||
| We are the first in class pre-clinical translational biophysics company focusing on the discovery of novel therapeutics against intrinsically disordered targets. | $40M / Series A / Jun 09, 2022 | ||
| Rimsys is a world-leading Regulatory Information Management (RIM) software for medical technology companies. Built by and for regulatory affairs professionals, Rimsys digitizes, automates, and creates regulatory order to ensure products adhere to changing global regulations. It is the only holistic RIM software for medical devices, in-vitrodiagnostics, and medical device software that makes it easy to manage global UDI requirements and navigate the pillars of regulatory affairs, including product registration, standards management, essential principles/GSPR, and regulatory intelligence. | $16M / Series A / Dec 02, 2021 | ||
| Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation. It features a proprietary predictive modeling degradation platform with a novel small molecule modality to accelerate the drug discovery designed for disease-causing proteins. | $102M / Series C / Mar 12, 2020 | ||
| Bright Health Group is a health insurance company that delivers affordable healthcare to aging and underserved populations. Bright Health aims to improve the healthcare experience by leveraging technology to streamline operations and enhance member engagement. They focus on building partnerships with health systems and care providers to createintegrated healthcare networks. By forming these partnerships, Bright Health seeks to offer its members a more personalized and coordinated healthcare experience.The company differentiates itself by utilizing data analytics and digital tools to help both its members and healthcare providers make more informed decisions about healthcare. They strive to simplify the complexities of health insurance and improve access to quality care for their customers. | $635M / Series D / Dec 17, 2019 | ||
| See all 20 investments → | |||
Co-Investors
Bessemer Venture Partners is a venture capital firm that invests in early-stage and growth-stage companies across technology, healthcare, and consumer sectors. It provides capital to startups and emerging businesses while supporting founders with strategic guidance, operational insight, and network access. The firm participates in multiple funding stages, from seed investments to later growth rounds, and works closely with portfolio companies on product development, market expansion, and organizational scaling. Its investment activities span software, cloud infrastructure, fintech, biotech, and internet-enabled businesses, aligning capital deployment with long-term company building.
Bessemer Venture Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Aia Sarycheva
Investor
|
|||
Alexandra Sukin
Investor
|
|||
Anant Vidur Puri
Partner
|
|||
|
Andrew Hedin
Partner
|
|||
Caty Rae
Investor
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Andrew Hedin invest in?
Andrew Hedin invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Seed stage. Most of the 20 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Andrew Hedin?
Public channels for Andrew Hedin include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Andrew Hedin last invest?
The most recent investment recorded for Andrew Hedin closed in Oct 2026. Shizune tracks 20 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
